Your browser doesn't support javascript.
loading
MYC sensitises cells to apoptosis by driving energetic demand.
Edwards-Hicks, Joy; Su, Huizhong; Mangolini, Maurizio; Yoneten, Kubra K; Wills, Jimi; Rodriguez-Blanco, Giovanny; Young, Christine; Cho, Kevin; Barker, Heather; Muir, Morwenna; Guerrieri, Ania Naila; Li, Xue-Feng; White, Rachel; Manasterski, Piotr; Mandrou, Elena; Wills, Karen; Chen, Jingyu; Abraham, Emily; Sateri, Kianoosh; Qian, Bin-Zhi; Bankhead, Peter; Arends, Mark; Gammoh, Noor; von Kriegsheim, Alex; Patti, Gary J; Sims, Andrew H; Acosta, Juan Carlos; Brunton, Valerie; Kranc, Kamil R; Christophorou, Maria; Pearce, Erika L; Ringshausen, Ingo; Finch, Andrew J.
Afiliação
  • Edwards-Hicks J; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Su H; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, Stübeweg 51, D-79108, Freiburg, Germany.
  • Mangolini M; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Yoneten KK; Wellcome Trust/MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, CB2 0AH, UK.
  • Wills J; Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
  • Rodriguez-Blanco G; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Young C; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Cho K; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Barker H; Department of Chemistry and Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA.
  • Muir M; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Guerrieri AN; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Li XF; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • White R; MRC University of Edinburgh Centre for Reproductive Health, University of Edinburgh, Edinburgh, EH16 4TJ, UK.
  • Manasterski P; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Mandrou E; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Wills K; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Chen J; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Abraham E; Wellcome Trust/MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, CB2 0AH, UK.
  • Sateri K; Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
  • Qian BZ; Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
  • Bankhead P; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Arends M; MRC University of Edinburgh Centre for Reproductive Health, University of Edinburgh, Edinburgh, EH16 4TJ, UK.
  • Gammoh N; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • von Kriegsheim A; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Patti GJ; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Sims AH; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Acosta JC; Department of Chemistry and Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA.
  • Brunton V; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Kranc KR; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Christophorou M; Instituto de Biomedicina y Biotecnología de Cantabria, IBBTEC (CSIC, Universidad de Cantabria). C/ Albert Einstein 22, Santander, 39011, Spain.
  • Pearce EL; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Ringshausen I; Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
  • Finch AJ; MRC Center for Regenerative Medicine, University of Edinburgh, Edinburgh, EH8 9YL, UK.
Nat Commun ; 13(1): 4674, 2022 08 09.
Article em En | MEDLINE | ID: mdl-35945217
ABSTRACT
The MYC oncogene is a potent driver of growth and proliferation but also sensitises cells to apoptosis, which limits its oncogenic potential. MYC induces several biosynthetic programmes and primary cells overexpressing MYC are highly sensitive to glutamine withdrawal suggesting that MYC-induced sensitisation to apoptosis may be due to imbalance of metabolic/energetic supply and demand. Here we show that MYC elevates global transcription and translation, even in the absence of glutamine, revealing metabolic demand without corresponding supply. Glutamine withdrawal from MRC-5 fibroblasts depletes key tricarboxylic acid (TCA) cycle metabolites and, in combination with MYC activation, leads to AMP accumulation and nucleotide catabolism indicative of energetic stress. Further analyses reveal that glutamine supports viability through TCA cycle energetics rather than asparagine biosynthesis and that TCA cycle inhibition confers tumour suppression on MYC-driven lymphoma in vivo. In summary, glutamine supports the viability of MYC-overexpressing cells through an energetic rather than a biosynthetic mechanism.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apoptose / Glutamina Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apoptose / Glutamina Idioma: En Ano de publicação: 2022 Tipo de documento: Article